Consequences of regulated pre-mRNA splicing in the immune system

Nature Reviews Immunology

Volumn 4, Issue 12, 2004, Pages 931-940

  Lynch, Kristen W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CD31 ANTIGEN; CD45 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; CYTOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 15; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; MESSENGER RNA; MESSENGER RNA PRECURSOR; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; T LYMPHOCYTE RECEPTOR;

ALTERNATIVE RNA SPLICING; ASTHMA; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; GENE EXPRESSION REGULATION; GRAVES DISEASE; HUMAN; HUMAN CELL; IMMUNE SYSTEM; LYMPHOCYTE MIGRATION; MULTIGENE FAMILY; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RNA SPLICING; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION;

ALTERNATIVE SPLICING; ANTIGENS, CD44; ANTIGENS, CD45; IMMUNE SYSTEM; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES;

EID: 10244239317     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1497     Document Type: Review

References (88)

1. Modrek, B., Resch, A., Grasso, C. & Lee, C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res. 29, 2850-2859 (2001). This study demonstrates the extent of alternative splicing in humans, particularly in the immune and nervous systems.
2. Johnson, J. M. et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302, 2141-2144 (2003).
3. Black, D. L. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 72, 291-336 (2003).
4. Smith, C. W. J. & Valcarcel, J. Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem. Sci. 25, 381-388 (2000).
5. Black, D. L. & Grabowski, P. J. Alternative pre-mRNA splicing and neuronal function. Prog. Mol. Subcell. Biol. 31, 187-216 (2003).
6. Wu, J. Y., Tang, H. & Havlioglu, N. Alternative pre-mRNA splicing and regulation of programmed cell death. Prog. Mol. Subcell. Biol. 31, 153-185 (2003).
7. Black, D. Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology. Cell 103, 367-370 (2000).
8. Graveley, B. R. Alternative splicing: increasing diversity in the proteomic world. Trends Genet. 17, 100-107 (2001).
9. Wollerton, M. C., Gooding, C., Wagner, E. J., Garcia-Blanco, M. A. & Smith, C. W. Autoregulation of polypyrimidine tract binding protein by alternative splicing leading to nonsense-mediated decay. Mol. Cell 13, 91-100 (2004).
10. Ishitani, A. & Geraghty, D. E. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc. Natl Acad. Sci. USA 89, 3947-3951 (1992).
11. Van, G., Shi, L. & Faustman, D. Novel splicing of the human MHC-encoded peptide transporter confers unique properties. J. Immunol. 162, 852-859 (1999).
12. + cells. J. Immunol. 152, 201-212 (1994).
13. Atkinson, T. P., Hall, C. G., Goldsmith, J. & Kirkham, P. M. Splice variant in TCRζ links T cell receptor signaling to a G-protein-related signaling pathway. Biochem. Biophys. Res. Commun. 310, 761-766 (2003).
14. Tsytsikov, V. N., Yurovsky, V. V., Atamas, S. P., Alms, W. J. & White, B. Identification and characterization of two alternative splice variants of human interleukin-2. J. Biol. Chem. 271, 23055-23060 (1996).
15. Alms, W. J., Atamas, S. P., Yurovsky, V. V. & White, B. Generation of a variant of human interleukin-4 by alternative splicing. Mol. Immunol. 33, 361-370 (1996).
16. Trowbridge, I. S. & Thomas, M. L. CD45: An emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu. Rev. Immunol. 12, 85-116 (1994).
17. Oaks, M. K. et al. A native soluble form of CTLA-4. Cell. Immunol. 201, 144-153 (2000).
18. Arch, R. et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 257, 682-685 (1992).
19. Rothrock, C., Cannon, B., Hahm, B. & Lynch, K. W. A conserved signal-responsive sequence mediates activation-induced alternative splicing of CD45. Mol. Cell 12, 1317-1324 (2003). Identification of the important sequences in the CD45 variable exons that mediate their antigen-induced repression. Evidence is also provided for the existence of common splicing-regulatory pathways in T cells
20. Cooke, M. P. & Perlmutter, R. M. Expression of a novel form of the fyn proto-oncogene in hematopoietic cells. New Biol. 1, 66-74 (1989).
21. Davidson, D., Viallet, J. & Veillette, A. Unique catalytic properties dictate the enhanced function of p59fynT, the hemopoietic cell-specific isoform of the Fyn tyrosine protein kinase, in T cells. Mol. Cell Biol. 14, 4554-4564 (1994). This paper provides a detailed analysis of the functional differences between the FYN isoforms.
22. Davidson, D., Chow, L. M., Fournel, M. &,Veillette, A. Differential regulation of T cell antigen responsiveness by isoforms of the src-related tyrosine protein kinase p59fyn. J. Exp. Med. 175, 1483-1492 (1992).
23. Weil, R. et al. Altered expression of tyrosine kinases of the Src and Syk families in human T-cell leukemia virus type 1-infected T-cell lines. J. Virol. 73, 3709-3717 (1999).
24. Germani, A., Malherbe, S. & Rouer E. The exon 7-spliced Lck isoform in T lymphocytes: a potential regulator of p56lck signaling pathways. Biochem. Biophys. Res. Commun. 301, 680-685 (2003).
25. Rowley, R. B., Bolen, J. B. & Fargnoli, J. Molecular cloning of rodent p72Syk. Evidence of alternative mRNA splicing. J. Biol. Chem. 270, 12659-12664 (1995).
26. Yagi, S., Suzuki, K., Hasegawa, A., Okumura, K. & Ra, C. Cloning of the cDNA for the deleted Syk kinase homologous to ZAP-70 from human basophilic leukemia cell line (KU812). Biochem. Biophys. Res. Commun. 200, 28-34 (1994).
27. Latour, S., Zhang, J., Sraganian, R. P. & Veillette A. A unique insert in the linker domain of Syk is necessary for its function in immunoreceptor signalling. EMBO J. 17, 2584-2595 (1998). The authors identify the molecular basis of the distinct functions of SYK and SYKB. This work also has implications for the functional difference between SYK and ZAP70 (ζ-chain-associated protein kinase of 70 kDa).
28. King, P. D. et al. Novel isoforms of murine intercellular adhesion molecule-1 generated by alternative RNA splicing. J. Immunol. 154, 6080-6093 (1995).
29. Wang, Y. & Sheibani, N. Expression pattern of alternatively spliced PECAM-1 isoforms in hematopoietic cells and platelets. J. Cell. Biochem. 87, 424-438 (2002).
30. Robledo, O. et al. ICAM-1 isoforms: specific activity and sensitivity to cleavage by leukocyte elastase and cathepsin G. Eur. J. Immunol. 33, 1351-1360 (2003).
31. Wang, Y., Su, X., Sorenson, C. M. & Sheibani, N. Modulation of PECAM-1 expression and alternative splicing during differentiation and activation of hematopoietic cells. J. Cell. Biochem. 88, 1012-1024 (2003).
32. Fox, S. B. et al. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res. 54, 4539-4546 (1994).
33. Ponta, H., Sherman, L. & Herrlich, P. A. CD44: from adhesion molecules to signalling regulators. Nature Rev. Mol. Cell Biol. 4, 33-45 (2003).
34. Gunthert, U. et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65, 13-24 (1991).
35. Eisterer, W. et al. CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma. Leuk. Res. 25, 1051-1057 (2001).
36. Bartolazzi, A. et al. Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. J. Cell Sci. 108, 1723-1733 (1995).
37. Konig, H., Ponta, H. & Herrlich, P. Coupling of signal transduction to alternative pre-mRNA splicing by a composite splice regulator. EMBO J. 17, 2904-2913 (1998).
38. Atamas, S. P. Alternative splice variants of cytokines: making a list. Life Sci. 61, 1105-1112 (1997).
39. Heaney, M. L. & Golde, D. W. Soluble cytokine receptors. Blood 81, 847-857 (1996).
40. + T cells. J. Exp. Med. 185, 461-469 (1997).
41. Xu, G. Y. et al. Solution structure of recombinant human interleukin-6. J. Mol. Biol. 268, 468-481 (1997).
42. Somers, W., Stahl, M. & Seehra, J. S. 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J. 16, 989-997 (1997).
43. Boulay, J. L. & Paul, W. E. The interleukin-4-related lymphokines and their binding to hematopoietin receptors. J. Biol. Chem. 267, 20525-20528 (1992).
44. Bihl, M. P. et al. Identification of a novel IL-6 isoform binding to the endogenous IL-6 receptor. Am. J. Respir. Cell. Mol. Biol. 27, 48-56 (2002). An excellent study of the structure-function relationship between IL-6 isoforms.
45. Paonessa, G. et al. Two distinct and independent sites on IL-6 trigger gp130 dimer formation and signalling. EMBO J. 14, 1942-1951 (1995).
46. Zav'yalov, V. P. et al. Molecular model of an alternative splice variant of human IL-4, IL-4Δ2, a naturally occurring inhibitor of IL-4-stimulated T cell proliferation. Immunol. Lett. 58, 149-152 (1997).
47. Denesyuk, A. I., Zav'yalov, V. P., Denessiouk, K. A. & Korpela, T. Molecular models of two competitive inhibitors, IL-2Δ2 and IL-2Δ3, generated by alternative splicing of human interieukin-2. Immunol. Lett. 60, 61-66 (1998).
48. Kruse, S., Forster, J., Kuehr, J. & Deichmann, K. A. Characterization of the membrane-bound and a soluble form of human IL-4 receptor α produced by alternative splicing. Int. Immunol. 11, 1965-1970 (1999).
49. Goodwin, R. G. et al. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell 60, 941-951 (1990).
50. Miyazaki, T. et al. Pyk2 is a downstream mediator of the IL-2 receptor-coupled Jak signaling pathway. Genes Dev. 12, 770-775 (1998).
51. Benbemou, N., Muegge, K. & Durum, S. K. Interleukin (IL)-7 induces rapid activation of Pyk2, which is bound to Janus kinase 1 and IL-7Rα. J. Biol. Chem. 275, 7060-7065 (2000).
52. Hazeki, K. et al. Toll-like receptor-mediated tyrosine phosphorylation of paxillin via MyD88-dependent and -independent pathways. Eur. J. Immunol. 33, 740-747 (2003).
53. Dikic, I. & Schlessinger, J. Identification of a new Pyk2 isoform implicated in chemokine and antigen receptor signaling. J. Biol. Chem. 273, 14301-14308 (1998). Identification and functional characterization of a variant isoform of PYK2.
54. Cao, Z., Henzel, W. J. & Gao, X. IRAK: a kinase associated with the interleukin-1 receptor. Science 271, 1128-1131 (1996).
55. Jensen, L. E. & Whitehead, A. S. IRAK1b, a novel alternative splice variant of interleukin-1 receptor-associated kinase (IRAK), mediates interleukin-1 signaling and has prolonged stability. J. Biol. Chem. 276, 29037-29044 (2001).
56. Wesche, H., Henzel, W. J., Shillinglaw, W., Li, S. & Cao, Z. MyD88: an adapter that recruits IRAK to 1he IL-1 receptor complex. Immunity 7, 837-847 (1997).
57. Burns, K. et al. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 197, 263-268 (2003). This paper clearly shows the molecular basis for the functional differences between MyD88 isoforms.
58. Janssens, S., Burns, K., Tschopp, J. & Beyaert, R. Regulation of interleukin-1- and lipopolysaccharide-induced NF-κB activation by alternative splicing of MyD88. Curr. Biol. 12, 467-471 (2002).
59. Lynch, K. W. & Weiss, A. A model system for the activation-induced alternative-splicing of CD45 implicates protein kinase C and Ras. Mol. Cell Biol. 20, 70-80 (2000).
60. Xu, Z. & Weiss, A. Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nature Immunol. 3, 764-771 (2002). This study demonstrates the functional differences between CD45 isoforms due to the inefficiency of dimerization of the large CD45 isoforms.
61. Majeti, R., Bilwes, A. M., Noel, J. P., Hunter, T. & Weiss, A. Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge. Science 279, 88-91 (1998).
62. Hermiston, M. L., Xu, Z., Majeti, R. & Weiss, A. Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases. J. Clin. Invest. 109, 9-14 (2002).
63. Jacobsen, M. et al. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nature Genet. 26, 495-499 (2000).
64. Chu, D. H. et al. The Syk protein tyrosine kinase can function independently of CD45 and Lck in T cell antigen receptor signaling. EMBO J. 15, 6251-6261 (1996).
65. van der Merwe, P. A., Bodian, D. L., Daenke, S., Linsley, P. & Davis, S. J. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J. Exp. Med. 185, 393-403 (1997).
66. Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465 (1995).
67. Perkins, D. et al. Regulation of CTLA-4 expression during T cell activation. J. Immunol. 156, 4154-4159 (1996).
68. Magistrelli, G. et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol. 29, 3596-3602 (1999).
69. Faustino, N. A. & Cooper, T. A. Pre-mRNA splicing and human disease. Genes Dev. 17, 419-437 (2003).
70. Cartegni, L., Chew, S. L. & Krainer, A. R. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nature Rev. Genet. 3, 285-298 (2002).
71. Pagani, F. & Baralle, F. E. Genomic variants in exons and introns: identifying the splicing spoilers. Nature Rev. Genet. 5, 389-396 (2004).
72. Oaks, M. K. & Hallett, K. M. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J. Immunol. 164, 5015-5018 (2000).
73. Ueda, H. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506-511 (2003).
74. Jones, S. A., Horiuchi, S., Topley, N., Yamamoto, N. & Fuller, G. M. The soluble interleukin-6 receptor: mechanisms of production and implications in disease. FASEB J. 15, 43-58 (2001).
75. Korte, A. et al. Expression analysis and characterization of alternatively spliced transcripts of human IL-7Rα chain encoding two truncated receptor proteins in relapsed childhood all. Cytokine 12, 1597-1608 (2000).
76. Kotsimbos, A. T. & Hamid, Q. IL-5 and IL-5 receptor in asthma. Mem. Inst. Oswaldo Cruz 92, 75-91 (1997).
77. Sakkas, L. I., Tourtellotte, C., Berney, S., Myers, A. R. & Platsoucas, C. D. Increased levels of alternatively spliced interleukin 4 (IL-4Δ2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin. Diagn. Lab. Immunol. 6, 660-664 (1999).
78. Matter, N. et al. Heterogeneous ribonucleoprotein A1 is part of an exon-specific splice-silencing complex controlled by oncogenic signaling pathways. J. Biol. Chem. 275, 35353-35360 (2000).
79. Weg-Remers, S., Ponta, H., Herrlich, P. & Konig, H. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J. 20, 4194-4203 (2001).
80. Matter, N., Herrlich, P. & Konig, H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420, 691-695 (2002). This is one of the first papers to provide a clear molecular link between activation of the mitogen-activated protein kinase pathway and modulation of a specific splicing regulatory event.
81. Stickeler, E. et al. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J. 20, 3821-3830 (2001).
82. Honig, A., Auboeuf, D., Parker, M. M., O'Malley, B. W. & Berget, S. M. Regulation of alternative splicing by the ATP-dependent DEAD-box RNA helicase p72. Mol. Cell Biol. 22, 5698-5707 (2002).
83. Lynch, K. W. & Weiss, A. A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer. J. Biol. Chem. 276, 24341-24347 (2001).
84. Zilch, C. F. et al. A point mutation within CD45 exon A is the cause of variant CD45RA splicing in humans. Eur. J. Immunol. 28, 22-29 (1998).
85. H2 cells. Oncogene 22, 4636-4641 (2003).
86. Liu, C., Cheng, J. & Mountz, J. D. Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. Biochemistry J. 310, 957-963 (1995).
87. Nishimura, H., Washizu, J., Nakamura, N., Enomoto, A. & Yoshikai, Y. Translational efficiency B upregulated by alternative exon in murine IL-15 mRNA. J. Immunol. 160, 936-942 (1998).
88. Berget, S. M. Exon recognition in vertebrate splicing. J. Biol. Chem. 270, 2411-2414 (1995).